AzTrials
AzTrials

Maxillary ExpansionNCT06937775

Rapid Maxillary Expansion Related Oxidative Stress and Periodontal Results

A study testing Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Biochemical Sample Supply (Collection of serum and saliva samples) and Rapid maxillary expansion with Hyrax appliance in people with Maxillary Expansion, run by Recep Tayyip Erdogan University Training and Research Hospital.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study was to investigate the effects of rapid maxillary expansion on local and systemic oxidative stress levels. Thirty-five volunteer patients (17 females and 18 males) who needed rapid maxillary expansion will be included in the study. Read more about this study

Who is it for?
Ages 11 to 16 years
Conditions the study is for
Maxillary Expansion
What is being tested?
Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Biochemical Sample Supply (Collection of serum and saliva samples) and Rapid maxillary expansion with Hyrax appliance
Could I receive a placebo?
No, everyone receives an active treatment
How many people
35 participants
Where
No sites listed yet
Study dates
10 Jan 2016to 10 Aug 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 11 to 16 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Being between 11-15 years of age,
  • Having an indication for maxillary expansion due to maxillary stenosis,
  • Being highly cooperative, performing adequate oral care,
  • Being periodontally healthy,
  • Not having cleft lip and/or palate anomalies,
  • Not having any systemic disease,
  • Not having used any medication including antibiotics and anti-inflammatory drugs in the last 6 months,
  • Not being substance addicted and not smoking.

Who cannot join

  • Having inadequate oral hygiene
  • Being periodontally unhealthy
  • Having cleft lip and/or palate anomalies,
  • Having any systemic disease,
  • Having used any medication including antibiotics and anti-inflammatory drugs in the last 6 months,
  • Being substance addicted and not smoking.

About this study

Official title: Rapid Maxillary Expansion Related Sutural and Dentoalveolar Changes Provoke Salivary Oxidative Stress: A Biochemical Study

The aim of this study was to investigate the effects of rapid maxillary expansion on local and systemic oxidative stress levels. Thirty-five volunteer patients (17 females and 18 males) who needed rapid maxillary expansion will be included in the study. Serum and saliva samples will be collected from each patient during four different periods: a week before the treatment (T0), on the day of sutural separation (T1), at the end of the active expansion period (T2), and after the completion of a 3-month retention period (T3). To evaluate the patients' periodontal status, plaque index, gingival index, and probing pocket depth scores will be recorded for each period. 8-hydroxydeoxyguanosine (8-OHdG), total oxidative status (TOS), total antioxidant capacity (TAS), and oxidative stress index (OSI) biomarkers will be evaluated to determine the local and systemic oxidative stress levels.

Being tested
Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Biochemical Sample Supply (Collection of serum and saliva samples), Rapid maxillary expansion with Hyrax appliance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Periodontal measurements (plaque index, gingival index and probing pocket depth scores )Other

    Plaque index (PI), gingival index (GI) and probed pocket depth (PPD) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status and oral care effectiveness of the participants. PPD is the distance between the gingival margin and the sulcus base. Measurements will be made at 6 different sites (mesio-vestibular, vestibular, disto-vestibular, mesio-oral, oral, disto-oral) of each tooth using a Williams periodontal probe (Hu Friedy, Chicago, Illinois, USA). During the measurements, care will be taken to position the probe as parallel as possible to the long axis of the tooth and not to apply excessive force.

  • Biochemical Sample Supply (Collection of serum and saliva samples)Other

    Serum and saliva samples will obtained from all individuals included in the study at T0, T1, T2 and T3 for biochemical analyses.

    For standardisation purposes, blood samples will be collected from the antecubital fossa with the patients in a sitting position. After resting for 30 minutes (min) at room temperature, the samples will be centrifuged (4ºC at 3000 rpm for 5 min) and serum samples will be obtained. The samples will be transferred into eppendorf tubes and stored in the freezer (-80ºC) until the study day.

    Sampling will be performed early in the morning. Participants will be warned not to consume anything other than water for the last 12 hours and not to brush their teeth that morning. Individuals will be left with their mouths open for 5 min to allow saliva to accumulate at the floor of the mouth. Unstimulated saliva samples accumulated at the floor of the mouth will be collected and transferred to eppendorf tubes.

  • Rapid maxillary expansion with Hyrax applianceProcedure or surgery

    Rapid maxillary expansion (RME) is the most commonly preferred treatment of skeletal jaw stenosis in the transversal direction. Bilateral anchorage is the process of increasing the transversal dimension of the midpalatal suture (sutura palatina media) by applying strong tensile forces in the lateral direction to the dentoalveolar structures of the teeth and/or palatal bone. The primary goal of treatment is to provide orthopedic movement through sutural separation.

Study groups in NCT06937775
Study groupRoleWhat they receive
TOOther1 week before the placement of the Hyrax appliance
Receives: Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ); Other: Biochemical Sample Supply (Collection of serum and saliva samples)
T1OtherThe day of the first clinical observation of sutural opening (5-7 days after activation)
Receives: Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ); Other: Biochemical Sample Supply (Collection of serum and saliva samples); Procedure: Rapid maxillary expansion with Hyrax appliance
T2OtherThe day of completion of active expansion (3-4 weeks)
Receives: Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ); Other: Biochemical Sample Supply (Collection of serum and saliva samples); Procedure: Rapid maxillary expansion with Hyrax appliance
T3OtherThe day of completion of the 3-month reinforcement period
Receives: Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ); Other: Biochemical Sample Supply (Collection of serum and saliva samples); Procedure: Rapid maxillary expansion with Hyrax appliance

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Biochemical analyses - 8-OHdG

    8-OHdG is the most frequently encountered and best known mutagenicity of more than 20 oxidative base damage products of ROS in DNA. Since it is easily detected in living cells and body fluids, it is the most commonly used oxidative DNA damage marker.

    Serum and saliva levels will be measured using a suitable ELISA kit (Cayman Chemical DNA/RNA Oxidative Damage ELISA Kit Item No.589320) according to the manufacturer's instructions. The measurement principle is as follows: It is based on the competition between 8-OHdG from the sample and 8-OHdG-acetylcholinestarase conjugate (8- OHdG Tracer) from the kit for a limited amount of 8-OHdG monoclonal antibody covering the plate well. The colour intensity measured spectrophotometrically at 410 nm is directly proportional to the tracer and inversely proportional to the amount of free 8-OHdG in the sample.

    Measured: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

  2. Biochemical analyses - Oxidative Stress Index (TOS/TAS=OSI)

    Total Oxidative Status (TOS) is a current method used to detect lipid peroxidation and oxidative stress. TOS is considered to be a superior method compared to other methods due to the impracticality of measuring different oxidant molecules individually and the inability to fully reflect the interaction of oxidant molecules with each other. Total Antioxidan Status (TAS) is a biochemical parameter obtained as a result of the sum of the antioxidant capacities of all antioxidants in the biological samples examined. Oxidative Stress Index (OSI) is a proportional value obtained by dividing TOS by TAS. It is directly affected by total oxidative and antioxidant status and reveals the final oxidative status in a practical and understandable way.

    OSI value was calculated according to the following formula. OSI = TOS (mmol H2O2 Equiv./L) / TAS (mmol Trolox Equiv./L) x 100

    Measured: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

Secondary outcomes (3)
  1. Clinical Periodontal Assessments-plaque index

    Plaque index (PI) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status and oral care effectiveness of the participants. The amount and thickness of plaque causing gingival inflammation will be determined. The teeth will be dried by spraying light air and isolated. Each tooth will be scored by measuring with a probe from the gingival margin in six areas (mesiobuccal, distobuccal, mesial, distal, oral, vestibule).

    Measured: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

  2. Clinical Periodontal Assessments-gingival index

    Gingival index (GI) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status of the participants. The periodontal probe will be placed in the gingival sulcus parallel to the long axis of the teeth from the gum edge. Measurements will be made from the area under the teeth and scoring will be done according to the surface characteristics of the gum. The value found will be divided by the number of teeth and the gingival index will be determined for the entire mouth.

    Measured: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

  3. Clinical Periodontal Assessments-probed pocket depth (PPD)

    PPD is the distance between the gingival margin and the sulcus base. Measurements will be made at 6 different sites (mesio-vestibular, vestibular, disto-vestibular, mesio-oral, oral, disto-oral) of each tooth using a Williams periodontal probe (Hu Friedy, Chicago, Illinois, USA). During the measurements, care will be taken to position the probe as parallel as possible to the long axis of the tooth and not to apply excessive force.

    Measured: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Apr 2025
  2. Study start10 Jan 2016
  3. Primary completion10 Mar 2016
  4. Study completion10 Aug 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
35 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06937775
Sponsor's protocol ID
BAP 2015/306
Status last verified
Apr 2025
First submitted
29 Mar 2025
Last updated
24 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Biochemical Sample Supply (Collection of serum and saliva samples) and Rapid maxillary expansion with Hyrax appliance in people with Maxillary Expansion, run by Recep Tayyip Erdogan University Training and Research Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Biochemical analyses - 8-OHdG (time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in